Secretion of gastric acid is tightly controlled by the neuroendocrine system of the stomach, formed by an interconnected network of nerves and different hormone-producing cell types, particularly G cells that release the hormone gastrin.

CGeneTech announced that the ALK inhibitor CGT-9475, which was independently developed by Shengshi Tyco, has been approved by the FDA to enter clinical trials aiming to evaluate the candidate's ability to overcome the issues of drug resistance and brain metastasis in the treatment of lung cancer.

Homology Medicines announced the details of its optimized, in vivo, one-time gene therapy product candidate, HMI-204, being developed for the treatment of metachromatic leukodystrophy (MLD).

Cullgen announced that the Chinese National Medical Products Administration (NMPA) has allowed the IND application for CG-001419, a first-in-class, selective, potent oral targeted protein tyrosine receptor kinase (TRK) degrader for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive cancers, which have been identified in numerous solid tumors including non-small cell lung, breast and pancreatic cancers.

Athira Pharma has presented data on the development and evaluation of novel orally bioavailable, blood-brain-barrier-penetrant small-molecule hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) positive modulators for the potential treatment of cognitive impairment.

Ceapro announced that it has entered into an additional research project expanding on the ongoing collaboration with McMaster University to develop an inhalable immuno-therapeutic/-prophylactic for COVID-19-induced lung fibrosis.

Researchers presented data from a study that aimed to investigate the mechanism by which extracellular vesicle (EV)-associated miRNAs are involved in the activation of autophagy and the development of chemoradiation resistance in advanced non-small cell lung cancer (NSCLC).

Beckley Psytech has synthesized new tryptamine analogues acting as 5-HT2A and/or 5-HT2B and/or 5-HT2C receptor agonists reported to be useful for the treatment of depression.

Reata Pharmaceuticals has described ursolic acid derivatives acting as nitric oxide (NO) production inhibitors and/or nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) activators reported to be useful for the treatment of cancer and inflammatory disorders, among other disorders.

E-Scape Bio has identified indazoles acting as leucine-rich repeat kinase 2 (LRRK2; dardarin) and/or LRRK2 (G2019S mutant) inhibitors reported to be useful for the treatment of Parkinson's dementia, multiple system atrophy, Lewy body dementia, Parkinson's disease and Alzheimer's disease.